Spero Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly56.1MTarget: Sufficient to fund operations into 2028
Utebzi (tebipenem pivoxil) Commercial Launch Progress QuarterlyTarget: US market availability by the end of 2026
Watch Items
- Utebzi (tebipenem pivoxil) US Commercial LaunchTrigger: Launch by end of 2026Action: Monitor GSK's commercialization activities, initial sales uptake, and subsequent milestone triggers.
- Cash Runway and Burn RateTrigger: Cash balance falling below $30 millionAction: Evaluate potential milestone receipts from GSK or explore strategic portfolio expansion opportunities.
Research as of 19 Jun 2026